This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e10. Learning Objective-Upon completion of this activity, successful learners will be able to identify the normal range of transient elastography exam of the liver in obese and nonobese patients, and be able to recognize the influence of different metabolic factors on this result.
BACKGROUND & AIMS:
Transient elastography (TE) is a noninvasive technique used to measure liver stiffness to estimate the severity of fibrosis. The range of liver stiffness measurements (LSMs) in healthy individuals is unclear. We performed a systematic review to determine the range of LSMs, examined by TE, in healthy individuals and individuals who are susceptible to fibrosis.
METHODS:
We collected data from 16,082 individuals, in 26 cohorts, identified from systematic searches of Embase, Ovid MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews for studies of liver stiffness measurements. Studies analyzed included apparently healthy adults (normal levels of liver enzymes, low-risk alcohol use patterns, and negative for markers of viral hepatitis). The presence of diabetes, hypertension, dyslipidemia, or steatosis, based on ultrasound examination, was known for most participants. We performed a meta-analysis of data from individual participants. The cohort was divided into 4 groups; participants with a body mass index <30 kg/m 2 were examined with the medium probe and those with a body mass index ‡30 kg/m 2 were examined with the extra-large probe. Linear regression models were conducted after adjusting for potential confounding factors of LSMs. We performed several sensitivity analyses.
RESULTS:
We established LSM ranges for healthy individuals measured with both probes-these did not change significantly in sensitivity analyses of individuals with platelets ‡150,000/mm 3 and levels of alanine aminotransferase £33 IU/L in men or £25 IU/L in women. In multivariate analysis, factors that modified LSMs with statistical significance included diabetes, dyslipidemia, waist circumference, level of aspartate aminotransferase, and systolic blood pressure at examination time. Significant increases in LSMs were associated with the metabolic syndrome in individuals examined by either probe. Diabetes in obese individuals increased the risk of LSMs in the range associated with advanced fibrosis.
CONCLUSIONS:
In a systematic review and meta-analysis of data from individual participants, we established a comprehensive set of LSM ranges, measured by TE in large cohorts of healthy individuals and persons susceptible to hepatic fibrosis. Regression analyses identified factors associated with increased LSMs obtained by TE with the medium and extra-large probes.
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H epatic fibrosis has prognostic significance because afflicted patients are at higher risk of developing cirrhosis. Although liver biopsy is considered the best available gold standard for assessing hepatic fibrosis, several tests have been developed to obtain noninvasive indirect evidence of hepatic fibrosis, and liver stiffness measurement (LSM) by transient elastography (TE) is one of those most widely used tools.
Since the introduction of TE in 2003, several studies have confirmed its role in the identification of different stages of liver fibrosis compared with the reference gold standard of liver biopsy in different liver diseases. The currently recognized normal values for TE-acquired LSM have been derived from a number of studies, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] the first of which was reported by Corpechot et al 5 and evaluated the influence of sex on LSM. Other studies have been conducted in different populations, and the currently proposed 95th percentile of TE (range, 6.8-8.4 kPa) overlaps with the early stage of fibrosis. 4, 10, 14 In addition, there is no consensus on how anthropomorphic characteristics or metabolic comorbidities influence the normal range of LSM in presumably healthy individuals. Identification of a range of normal values of TE that account for potential confounding factors contributing to liver stiffness is needed.
In this individual participant data (IPD) metaanalysis, we aimed to define the normal range of LSM measured by TE and factors influencing this range by synthesizing studies reporting healthy individuals or susceptible individuals with metabolic comorbidities. We did not attempt to examine the influence of different physiological states such as the nonfasting state or examine the factors influencing TE failure rates.
Methods
We developed an a priori protocol and followed the guidance of Preferred Reporting Items for Systematic Reviews and Meta-Analysis of Individual Participant Data statement (Supplement 1). 15 
Data Sources and Search Strategies
An experienced librarian conducted the search with input from the study ' 
Inclusion Criteria
Inclusion criteria were as follows. First, studies that explicitly described the recruitment of apparently healthy individuals, as well as studies using comparative control arms of healthy recruits. Second, individuals who were 18 years of age and older. Third, healthy individuals or susceptible individuals with the following chronic conditions: hypertension, dyslipidemia, hepatic steatosis on ultrasound, and diabetes mellitus. The definition of healthy individual, normal control, or susceptible individual was consistent among selected studies, in that it signified at least a lack of known/overt liver disease, and known status for the aforementioned chronic conditions. This was accomplished by a detailed history and physical examination, and determining any abnormality of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and viral hepatitis serology. Fourth, alcohol use of fewer than 21 units per week in men, and fewer than 14 units per week in women (a unit was defined as the equivalent of 10 g of ethanol). Fifth, the examination was performed with FibroScan using a standard medium (M) probe for nonobese individuals or an extra-large (XL) probe for obese individuals and documented in the data set. A justification for the use of either probe was provided from the study authors and this justification was similar across studies. Sixth, a technically good examination according to the manufacturer's instructions: individuals in a fasting state who had a minimum of 10 valid readings, with at least a 60% success rate and an interquartile range of 30% of the median value, with results expressed in kilopascals. For every participant, only average LSM value from all valid reads were collected, without collecting unreliable (not meeting the earlier-described criteria) or failed results (no value obtained after at least 10 measurements).
Exclusion Criteria
The exclusion criteria were as follows: (1) pregnancy or the presence of pacemaker, concordant with the manufacturer recommendations; (2) known overt liver disease (with the exception of hepatic steatosis discovered incidentally on abdominal ultrasound); (3) heavy alcohol use, defined as 5 or more drinks on the same occasion on each of 5 or more days in the past 30 days, 16 and/or more than 21 units per week in men and more than 14 units per week in women 17 (a unit was defined as the equivalent of 10 g of ethanol), determination of alcohol abuse was discussed with the primary investigators if the definition was not found in the text of study; and (4) use of a small probe (pediatric probe).
Data Extraction
Authors of screened studies potentially fulfilling the inclusion criteria were provided with the inclusion/ exclusion criteria and invited to provide related IPD. Supplement 3 lists the investigators who provided data sets, and investigators who could not provide IPD. 
Study Group Analysis

What You Need to Know
Background Transient elastography is a common technique that measures liver stiffness as surrogate of fibrosis severity, although ranges of this measurement in healthy individuals or those with metabolic comorbidities is unclear.
Findings
The mean stiffness in truly healthy nonobese individuals was 4.68 kPa (CI, 4.64-4.73). Statistically significant modifiers of stiffness included diabetes, dyslipidemia, waist circumference, AST, and systolic blood pressure.
Implications for patient care
Transient elastography-acquired stiffness should be interpreted in context of certain metabolic factors. Obese diabetics are at risk of harboring advanced fibrosis-range stiffness and may benefit from a more rigorous evaluation.
susceptibility (defined as the absence of hypertension, dyslipidemia, hepatic steatosis on ultrasound, and diabetes mellitus); group B: patients with hepatic steatosis on ultrasound (regardless of any other factor); group C: patients with diabetes mellitus (regardless of any other factor); and group D: patients with both hepatic steatosis on ultrasound and diabetes mellitus (regardless of any other factor).
The outcome of interest was LSM evaluated by TE (FibroScan) and expressed in kilopascals.
Assessment of Methodologic Quality
Two reviewers (F.B. and S.H.) assessed the methodologic quality of included studies by applying a modified form of the Newcastle-Ottawa Scale adapted to our cohort cohort study and examined by a third reviewer (M.H.M.). We kept items that focused on the representativeness of the cases and ascertainment of outcome and removed items that related to selection of the controls and comparability. 18 This resulted in 7 items with 3 possible answers for each question (yes, cannot tell, no) (Supplement 4). Disagreement was resolved by discussion between the 2 reviewers.
Sensitivity Analyses
We conducted 4 sensitivity analyses for individuals examined by M or XL probes: (1) LSM after excluding individuals with platelet counts less than 150,000/mm 3 ; (2) LSM after excluding individuals who had an ALT value greater than the normal value reported by the American College of Gastroenterology practice guideline for evaluation of abnormal liver chemistries (>33 IU/L for males and >25 IU/L for females) 19 ; (3) LSM in individuals with and without the metabolic syndrome (MS), we applied the criteria of Adult Treatment Panel III for the metabolic syndrome, which was updated by the American Heart Association and the National Heart Lung and Blood Institute in 2005 20 ; and (4) LSM in individuals with probable advanced fibrosis or cirrhosis. Potential associated risk factors were studied by regression model analysis and according to the cut-off values proposed previously 21 for the diagnosis of nonalcoholic fatty liver disease (NAFLD) (LSM >9.6 kPa or >9.3 kPa for M and XL probes, respectively). Probable advanced fibrosis and cirrhosis were grouped together because no definite cutoff values for the diagnosis of cirrhosis in NAFLD are known. 22 
Statistical Analysis and Regression Model Analysis
We performed descriptive analyses, reporting measures of means and 95% CIs for continuous variables and percentages for dichotomized variables. To evaluate the association between liver stiffness and confounding factors, we constructed 2-level, mixed-effect, linear, random-intercept, regression models with unconstructed covariance between the random effects. 23 The adjusted factors included age, sex, hepatic steatosis on ultrasound, waist circumference (WC) in cm, systolic blood pressure (SBP) and diastolic blood pressure (DBP) at examination time, diabetes mellitus, history of arterial hypertension, dyslipidemia, ALT and AST values, and smoking. Observations without providing all of the adjusted factors were deemed as missing and were ignored in the analyses. All statistical analyses were conducted using STATA version 14.1 (StataCorp LP, College Station, TX).
Results
Description of Included Studies
The flow diagram of the different phases of this individual participant data meta-analysis is shown in Figure 1 . Our search identified 2043 entries, in addition to 1 entry manually. Two reviewers (F.B. and S.H.) examined all entries. We identified 128 entries as potentially appropriate to be included if enough data were available. Emails were sent to corresponding and primary authors of unique entries (abstracts and articles) to obtain individual participant data tables. We excluded 53 studies that had fewer than 50 individuals, and 49 authors were not able to provide data (up to 3 emails sent as reminders, and co-authors on involved articles also were contacted when their contact information was found on the internet).
The study included 26 cohorts with a total of 16,082 individuals. The breakdown of these studies and references is outlined in Supplement 5.
Baseline Characteristics of Studies
Analysis of the data set showed the following characteristics (expressed in means AE Supplementary Figures 1 and 2 . Aside from a small cohort, the majority of included individuals did not undergo liver biopsy because the majority were deemed healthy, implying that a liver biopsy would be unethical, with unjustifiable risks.
Assessment of Methodologic Quality
Supplement 6 shows the assessment of methodologic quality for the 26 included cohorts, and Supplementary Figure 3 shows the overall risk of bias for these cohorts.
Normal Liver
2 ) examined by the XL probe for each of the 4 groups is shown in Table 1 . The mean stiffness for healthy nonobese individuals was 4.68 kPa (95% CI, 4.64-4.73). The LSM increased gradually for both probes from healthy individuals, to individuals with hepatic steatosis on ultrasound, to individuals with diabetes mellitus, and finally to individuals with both hepatic steatosis on ultrasound and diabetes mellitus.
Regression Analysis Model of Normal Liver Stiffness by Using the Medium and Extra-Large Probes
A regression model assessing confounding factors (adjusting for each factor) that influence LSM was developed for M and XL probes and restricted to individuals with a BMI <30 kg/m 2 and ‡30 kg/m 2 , respectively. The regression coefficient represents the kPa change in liver stiffness. Table 2 summarizes the results of this model. We elected to examine waist circumference rather than BMI because it can provide an estimate of increased abdominal fat even in the absence of a change in BMI, especially when the BMI is less than 35. For individuals examined by the M probe, diabetes mellitus, waist circumference, AST value, and SBP at examination time were associated with a statistically significant increase in LSM. Dyslipidemia was associated with a statistically significant decrease in LSM. The other adjusted factors had no significant effect on LSM. For individuals examined by the XL probe, waist circumference and SBP at examination time were associated with a statistically significant increase in LSM, whereas the other adjusted factors had no statistically significant effect on LSM.
We could not evaluate the influence of ethnicity on LSM owing to limited data. Of note, this regression analysis included LSM values of individuals who had available data for all of the adjusted factors, for example, if a participant's data included information regarding all adjusted variables except waist circumference, this participant was excluded from the analysis. This is in contrast to analysis of groups A to D, in which participants did not need to have all data values to be included.
Sensitivity Analyses
Sensitivity analyses after excluding individuals with platelets count less than 150,000/mm 3 , and after excluding individuals with an ALT level greater than the normal value reported by the American College of Gastroenterology practice guideline of abnormal liver chemistries (>33 U/L in males or >25 U/L in females) 19 ( Table 3) , showed similar ranges to the original analysis.
The metabolic syndrome was associated with a statistically significant increase of LSM in the whole cohort examined by M or XL probes, but had no effect in individuals with probable advanced fibrosis or cirrhosis (Table 4) .
Of these presumed healthy individuals, LSM suggestive of advanced fibrosis/cirrhosis was observed in 1.5% of individuals examined by the M probe (all with BMI <30 kg/m 2 and LSM >9.6 kPa) and in 6% of individuals examined by the XL probe (all with BMI ! 30 kg/m 2 and LSM >9.3 kPa). For individuals examined by either probe, DBP at examination time was associated with a decrease in the risk of probable advanced fibrosis or cirrhosis by regression model analysis (Supplement 7).
For individuals examined by the XL probe, diabetes mellitus and SBP at examination time was associated with an increased risk of advanced fibrosis or cirrhosis by regression model analysis. Figure 2 summarizes the results of LSM in the 4 groups, the factors influencing it, and the results of individuals with or without MS.
Discussion
Important factors, including waist circumference, presence of diabetes mellitus, increased AST level, dyslipidemia, and SBP at examination time, all impact the LSM obtained by TE and should be factored into the measured LSM output. Furthermore, these factors exert different effects on LSM depending on the probe used.
The LSM has supplanted liver biopsy and has become the hepatologist's stethoscope when approaching evaluation of liver fibrosis. However, increased liver stiffness is not equal to liver fibrosis and the influence of multiple potential confounding factors on the result of the test need to be taken into account.
Studies addressing the concept of normal liver stiffness struggle with what constitutes a healthy or normal individual. Several studies have defined healthy individuals as those with normal liver biochemical tests, no history of chronic liver disease, and an absence of hepatic steatosis on ultrasound. Other studies included individuals with hepatic steatosis on ultrasound. Few studies have considered the effects of comorbid conditions (diabetes, hyperlipidemia, hypertension, and liver steatosis on ultrasound) or the possibility of subclinical liver disease in reportedly normal or healthy individuals. We analyzed individualized patient data accounting for comorbid conditions that may impact liver stiffness values and/or the possibility of occult or subclinical liver disease with sufficient power to determine the effects of many confounding factors on LSM. Validation of the effect of confounding factors on LSM against the gold standard liver biopsy fibrosis score in diseased states is needed, and studies are underway to do so. Although increased waist circumference has been associated with an increased failure rate in measuring LSM, 24 whether waist circumference influences the normal range of LSM, when measurement is successful and valid, has been unclear. Most studies focused on BMI rather than waist circumference, with varying results. 3, 4, 6, 8, [10] [11] [12] 14, [25] [26] [27] [28] In this controlled regression model, in which LSM values were examined only for valid measurements, waist circumference was associated independently with increased LSM. Waist circumference is better than BMI for the diagnosis of central obesity, which is associated with chronic lowgrade inflammation accelerating insulin resistance and accumulation of hepatocellular fat, and thus could influence LSM.
Several studies have shown that MS increased LSM in apparently healthy individuals 6, 26 and this was observed in our whole cohort but not in a subgroup of individuals with probable advanced fibrosis or cirrhosis.
Similarly, some studies looking at diabetes and insulin resistance showed significantly higher LSMs, 14, 25, 29 whereas other studies did not. 10 In this study, the presence of diabetes mellitus had the largest effect on LSM, after controlling for all other variables, including hepatic steatosis on ultrasound. In addition, diabetes in obese individuals was a risk factor for the presence of advanced fibrosis or cirrhosis by regression model analysis.
Gan et al 3 showed a significant increase of LSM with increased SBP at examination time, and this was confirmed in our study of healthy individuals using the M and XL probes (ie, in all BMI ranges). 2, 11 Furthermore, a German group showed that increased arterial pressure, in the context of intense physical exercise in humans, is associated with an increase in LSM. 30 In addition, DBP at examination time was associated with a decreased risk of probable advanced fibrosis or cirrhosis-range LSM. The significance of this observation is not very well understood, but may be related to splanchnic circulation changes in the context of chronic liver disease.
Several studies have reported a significantly higher LSM in males than in females, [2] [3] [4] [5] [6] 12, 25 whereas other studies failed to show these differences. 7, 9, 13, 14, 31 After controlling for other important variables, sex was not associated with a statistically significant influence on LSM in this large study.
Previous studies might have not been powered enough to adjust for other important and confounding variables when looking at the influence of age, giving rise to associations that were not found in our current study.
The influence of dyslipidemia also is controversial. One study showed a significant increase of LSM in healthy individuals 3 whereas most studies did not. 8, 11, 14, 25 Interestingly, the presence of dyslipidemia actually was associated with a decreased LSM in our controlled regression model. This observed association remains unclear and unexplainable, considering the retrospective nature of the study and incompleteness of relevant parameters. Although we cannot provide a definite explanation for this phenomenon, one speculative possibility is that most of these patients likely were receiving lipid-lowering therapy after their diagnosis, and statins might have constituted the bulk of these medications. This class of drugs has been shown to potentially decrease intrahepatic vascular resistance through different mechanisms, 32, 33 which in turn is known to be associated directly with changes in LSM. It is noteworthy to mention that this association between an increase in splanchnic/portal pressure and LSM is the reason behind the recommendation of fasting before TE. 34 A recent systematic review with meta-analysis suggests that statin use might reduce the risk of hepatic decompensation, variceal bleeding, and mortality in patients with chronic liver disease. 35 However, it remains unknown whether statin use reduces LSM in healthy individuals.
A highly debated issue is the influence of simple hepatic steatosis on liver stiffness in patients with liver disease. Cournane et al 36 showed in an experimental study, using overlaying fat layers simulating in vivo conditions for obese patients, that somatic as well as hepatic fat overestimate the LSM. Alternatively, although Yoneda et al 37 showed that the LSM is not affected by the degree of steatosis, other groups have suggested that steatosis may decrease the stiffness of fibrotic liver. Thus, the impact of fibrosis on increasing LSM would be counterbalanced by the effect of co-existing steatosis. 38 In contrast, several studies have shown a significant increase of LSM in apparently healthy individuals with hepatic steatosis on ultrasound as compared with those without steatosis. 1, 8, 25, 39, 40 In this large diverse study population, although higher mean LSM values were noted in individuals with steatosis (Table 1) on regression analysis, ultrasound-detected steatosis had no effect on LSM in individuals examined by a M or XL probe. Notably, however, the degree of liver steatosis diagnosed by ultrasound was not determined in the provided data set.
A recent study of 1018 patients (afflicted with hepatitis B, C, or NAFLD) showed that smoking is associated with an increase in liver stiffness. 41 We were unable to confirm this finding because smoking was not associated with a significant increase of LSM in this study.
Transient elastography has been performed by several examiners in this cohort. This procedure is not difficult to learn and can be performed by individuals after minimal training of approximately 100 examinations according to the clinical practice guidelines of the European Association for the Study of the Liver and the Latino-American Association for the Study of the Liver. 42 Moreover, the results of TE are highly reproducible in studies assessing liver fibrosis in patients with chronic liver disease. 43 The strength of this study stems from the large cohort of individuals, from different centers and different ethnicities, selected after establishing a priori protocol with inclusion and exclusion criteria and use of both M and XL probes. Furthermore, we went to great lengths in excluding potential occult chronic liver disease, which could have confounded our results. This was performed through 2 layers: the rigorous inclusion criteria sent to all investigators, as well as the exclusion of individuals with thrombocytopenia or increased ALT level by current definitions. The percentage of individuals with LSM suggestive of advanced fibrosis or cirrhosis in this IPD is lower when compared with other studies. 44 A possible explanation is the exclusion of chronic viral hepatitis and excessive alcohol consumption in our cohort, which could have reduced confounders in our data. Moreover, our regression analysis conclusions are robust because the data were analyzed for a given LSM only if all variables of the regression analysis were available, and each variable therefore was controlled.
Early models of TE did not have the ability to automatically capture skin-to-capsule distance, and the device manual did not instruct physicians to perform an ultrasound to measure the skin-to-capsule distance. As such, an era effect likely was present in previous studies that were published early after the release of the device because individuals with large skin-to-capsule distance may have been examined inappropriately by the M probe, the only probe available on the market at that time. We have attempted to correct for this potential bias by establishing different ranges as they relate to the M probe and XL probe in nonobese and obese, but otherwise healthy, individuals.
This study had multiple inherent and unavoidable limitations that should be acknowledged. First, although identified by investigators as normal or healthy, hepatic fibrosis cannot be ruled out entirely in our cohort, and potentially could have contributed to the results. All of our analyses were performed with the assumption that there was no clinically significant fibrosis, and this may not have been an accurate assumption considering the retrospective nature of the data. Choosing healthy controls in clinical research is difficult, and some participants with unrecognized NAFLD could enter clinical trials as healthy controls and produce bias. 45 In the absence of the application of the best available gold standard (ie, liver histology), which was not offered to presumably healthy individuals for ethical reasons, we believe that making this assumption is clinically reasonable. Second, our data set did not capture the medications that susceptible individuals might have been taking, which is a major impediment in allowing full understanding of our results. Third, despite going to great lengths to ensure that inclusion/exclusion criteria were strict, we cannot rule out that an individual data set may not accurately have captured the presence or absence of certain factors such as the accurate degree of alcohol consumption and smoking when individuals were surveyed. However, all previous studies that evaluated normal liver stiffness have relied on surveys and history-taking to quantify alcohol consumption and this was an inherent limitation in any evaluation. Fourth, despite going to great lengths to encourage data sharing, some investigators could not share their individual participant data. Some of these studies have been deemed pivotal in defining normal liver stiffness. We have compensated for this shortcoming by obtaining a large data set that exceeds any study published on this topic. Fifth, all included patients were presumably healthy but subclinical fibrosis cannot be excluded, especially in the context of those patients with steatosis on ultrasound, because steatosis and fibrosis have a shared gene effect 46 and clearly genetic polymorphisms that predispose to hepatic steatosis also are associated with fibrosis severity (PNPLA3, TM6SF2). This is a recognized problem in evidence-based medicine, and does constitute a major limitation to nonprospective, as well as prospective, studies. 45 Sixth, determination of steatosis was performed by ultrasound, which has major limitations and reduced sensitivity. Controlled attenuation parameter exams were not available at the time of TE performance in the majority of included cohorts, and could be the modality of choice going forward. Finally, other ethnicities (eg, black, Middle Eastern) were underrepresented in this data set, despite the large cohort size, so applicability to this group of individuals may be less clear.
In conclusion, we establish a comprehensive set of normal LSM ranges for the M and XL probes as they relate to demographic characteristics, based on a large and diverse study population of healthy and susceptible individuals, balanced between the sexes, and covering all age groups. The mean stiffness for truly healthy nonobese individuals was 4.68 kPa (95% CI, 4.64-4.73), with LSM increasing with increasing metabolic comorbidity. We provide by regression analysis that metabolic factors that influence LSM that should be incorporated into the interpretation of LSM.
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